Professional Resource Managment of Wiregrass, LLC
Professional Resource Managment of Wiregrass, LLC was paid $748K by Medicaid between Jan 2018 and Oct 2024, across 41 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 51% of everything it billed.
33Billing provider infoPROFESSIONAL RESOURCE MANAGMENT OF WIREGRASS, LLC
OZARK, AL 36360
OZARK, AL 36360
33aNPI1740358837assigned 11/30/2006
33bProvider typeSpecialist
28Total paid$748K
24GClaims24,404
24DCodes billed41
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Specialist providers in Alabama
Rank by total paid#24 of 162
Median peer was paid$49K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,723 | $195K | |
| 2019 | 4,950 | $124K | |
| 2020 | 3,964 | $138K | |
| 2021 | 2,089 | $79K | |
| 2022 | 928 | $39K | |
| 2023 | 2,143 | $92K | |
| 2024incomplete | 1,607 | $81K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 51% | 9,132 | 5,971 | $382K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 10% | 480 | 368 | $77K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.6% | 833 | 582 | $56K |
| 99243 | 4.0% | 263 | 249 | $30K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 2.6% | 147 | 113 | $20K |
| 80061 | Lipid panel | 2.6% | 1,809 | 1,420 | $20K |
| 86769 | 2.4% | 719 | 302 | $18K | |
| Q3014 | Telehealth originating site facility fee | 1.7% | 873 | 659 | $13K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.5% | 76 | 68 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 1,105 | 898 | $11K |
| 87486 | 1.4% | 488 | 373 | $10K | |
| 87581 | 1.4% | 494 | 372 | $10K |
29 more codes
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.4% | 489 | $10K |
| 93000 | 1.2% | 636 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 225 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 1,734 | $8K |
| 94060 | <1% | 290 | $7K | |
| 94729 | <1% | 291 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 459 | $6K |
| 94727 | <1% | 291 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 72 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 241 | $4K |
| 82947 | <1% | 1,159 | $3K | |
| 94200 | <1% | 290 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 259 | $3K |
| 90674 | <1% | 132 | $2K | |
| 95816 | <1% | 20 | $2K | |
| 81025 | <1% | 520 | $1K | |
| 95819 | <1% | 14 | $1K | |
| 95923 | <1% | 33 | $962.00 | |
| 94010 | <1% | 57 | $936.00 | |
| 93922 | <1% | 37 | $760.00 | |
| 72100 | <1% | 38 | $630.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 38 | $607.54 |
| 95921 | <1% | 31 | $572.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 33 | $525.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 136 | $480.00 |
| 81002 | <1% | 178 | $378.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 238 | $229.34 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 23 | $3.96 |
| 71020 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILLEY, NANCY (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Professional Resource Management of Wiregrass, LLC | Dothan, AL | $8.99M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.